120% Payout: 2 Stocks Declared Rs 12/Share Interim Dividend For FY25; Do You Own Any?

Two organisations, Sasken Technologies and GlaxoSmithKline Pharmaceuticals, recently announced their financial results for the quarter that ended on September 30, 2024. Both companies have announced a dividend of Rs 12 per share for FY25 in addition to their impressive performance. Following the news, Sasken Technologies' shares closed Friday's trading session on the BSE 0.93% higher at Rs 1,709 per share, while GlaxoSmithKline Pharmaceuticals' shares concluded Friday's trading session 1.72% higher at Rs 2,723.20 per share.

Sasken Technologies Dividend

"The Board declared an interim dividend of Rs.12 (120%) per equity share of Rs. 10 each for the Financial Year 2024-25. As intimated vide our letter dated October 18, 2024, Board has fixed Tuesday, November 5, 2024, as the Record Date to ascertain the list of shareholders eligible for the aforesaid Interim Dividend and the same will be paid on or after Friday, November 8, 2024," said the company in a stock exchange filing.

Sasken Technologies Q2 Results

On a standalone basis, Sasken Technologies reported revenue from operations of Rs 112.40 crore in the September 2024 quarter up 31.91% from Rs. 85.21 crore in the September 2023 quarter. Its net profit stood at Rs. 10.83 crore in Q2FY25 down 53.01% from Rs. 23.04 crore in Q2FY24. EBITDA reached Rs. 20.86 crore in the quarter under review down 27.64% from Rs. 28.83 crore in the year-ago quarter.

Sasken Technologies News

"Pursuant to Regulations 29, 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the next meeting of the Board of Directors of the Company will be held on Saturday, November 9, 2024, to consider proposal for strategic investment and other business matters," informed Sasken Technologies to stock exchanges.

GlaxoSmithKline Pharmaceuticals Dividend

"The Board has recommended Special Interim dividend of Rs. 12/- (120%) per equity share on face value of Rs.10 each of the Company," said GlaxoSmithKline Pharmaceuticals in a stock exchange filing on 29th October 2024.

GlaxoSmithKline Pharmaceuticals Q2 Results

GSK, or GlaxoSmithKline Pharmaceuticals Limited, released its fiscal results for the quarter that ended on September 30, 2024. The quarter's revenue from operations increased by 5% to surpass Rs 1000 crores. The quarter's profit after tax (PAT), which was Rs 249 crores, increased by 15%. The firm generated Rs 1811 crores in revenue from operations for the half-year that ended on September 30, 2024, representing a 7% growth. With EBITDA margins at 30%, the half-year profit before exceptional items and tax, which was Rs 583 crores, increased by 27%.

Commenting on the results, Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders. Our performance reflects our commitment to sustainable growth and innovation. Furthermore, our shingles diseases awareness campaign featuring Mr. Amitabh Bachchan has significantly elevated the discussion around Shingles prevention, reinforcing our focus in preventive healthcare in India."